Sino Biopharmaceutical Ltd
HKEX:1177

Watchlist Manager
Sino Biopharmaceutical Ltd Logo
Sino Biopharmaceutical Ltd
HKEX:1177
Watchlist
Price: 3.22 HKD 0.31% Market Closed
Market Cap: 60.5B HKD
Have any thoughts about
Sino Biopharmaceutical Ltd?
Write Note

Sino Biopharmaceutical Ltd
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sino Biopharmaceutical Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Sino Biopharmaceutical Ltd
HKEX:1177
Pre-Tax Income
ÂĄ5.8B
CAGR 3-Years
-24%
CAGR 5-Years
-13%
CAGR 10-Years
12%
G
Grand Pharmaceutical Group Ltd
HKEX:512
Pre-Tax Income
HK$2.9B
CAGR 3-Years
3%
CAGR 5-Years
20%
CAGR 10-Years
33%
U
United Laboratories International Holdings Ltd
HKEX:3933
Pre-Tax Income
ÂĄ3.6B
CAGR 3-Years
42%
CAGR 5-Years
30%
CAGR 10-Years
11%
C
China Traditional Chinese Medicine Holdings Co Ltd
HKEX:570
Pre-Tax Income
ÂĄ817.2m
CAGR 3-Years
-31%
CAGR 5-Years
-16%
CAGR 10-Years
8%
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Pre-Tax Income
HK$16.9B
CAGR 3-Years
30%
CAGR 5-Years
11%
CAGR 10-Years
N/A
H
HUTCHMED (China) Ltd
HKEX:13
Pre-Tax Income
-$37.5m
CAGR 3-Years
39%
CAGR 5-Years
14%
CAGR 10-Years
N/A
No Stocks Found

Sino Biopharmaceutical Ltd
Glance View

Market Cap
59B HKD
Industry
Pharmaceuticals

Sino Biopharmaceutical Ltd. emerged as a key player in the Chinese healthcare landscape, rooted in the rich cultural hubs of Beijing and Hong Kong. As the tapestry of modern medicine interweaves ever more tightly with advanced research, Sino Biopharmaceutical positions itself at this critical juncture. The company delves extensively into the discovery, development, manufacturing, and commercialization of a broad spectrum of pharmaceuticals. With a keen focus on therapeutic areas like oncology, hepatitis, and cardio-cerebral diseases, they forge pathways for innovative treatments that resonate widely in the fast-developing Chinese medical market. Driven by its Research and Development prowess, Sino Biopharmaceutical garners considerable strength from its portfolio of proprietary drugs, underscoring a growth strategy deeply rooted in innovation and quality. The financial blueprint of Sino Biopharmaceutical delicately balances its expansive production capacities with a robust distribution network, encapsulating an effective end-to-end operation from lab to patient. Revenue streams are predominantly anchored in its extensive sales of prescription drugs, particularly high-margin specialty pharmaceuticals that address critical and chronic health conditions. Leveraging strategic alliances and collaborations with both domestic and international partners, the company enhances its technological capabilities and global reach. Moreover, its enduring commitment to sustainable practices and compliance wields influence over its operational efficiencies, allowing Sino Biopharmaceutical to navigate and capitalize on regulatory environments while meeting the burgeoning healthcare needs across its business region.

Intrinsic Value
3.97 HKD
Undervaluation 19%
Intrinsic Value
Price

See Also

What is Sino Biopharmaceutical Ltd's Pre-Tax Income?
Pre-Tax Income
5.8B CNY

Based on the financial report for Jun 30, 2024, Sino Biopharmaceutical Ltd's Pre-Tax Income amounts to 5.8B CNY.

What is Sino Biopharmaceutical Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
12%

Over the last year, the Pre-Tax Income growth was 28%. The average annual Pre-Tax Income growth rates for Sino Biopharmaceutical Ltd have been -24% over the past three years , -13% over the past five years , and 12% over the past ten years .

Back to Top